Stock Scorecard

Stock Summary for Protalix BioTherapeutics Inc (PLX) - $1.69 as of 11/20/2024 8:35:45 PM EST

Total Score

10 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PLX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PLX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PLX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PLX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PLX (15 out of 90)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0

Financial Details for PLX

Company Overview
Ticker PLX
Company Name Protalix BioTherapeutics Inc
Country USA
Description Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 1.69
Price 4 Years Ago 3.63
Last Day Price Updated 11/20/2024 8:35:45 PM EST
Last Day Volume 817,071
Average Daily Volume 306,745
52-Week High 1.90
52-Week Low 0.82
Last Price to 52 Week Low 106.10%

Valuation Measures
Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -1.99
Free Cash Flow Ratio 4.57
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 1.98
Total Cash Per Share 0.37
Book Value Per Share Most Recent Quarter 0.46
Price to Book Ratio 3.60
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 3.21
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 73,543,000
Market Capitalization 124,287,670
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 12.10%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY -39.20%
Annual Earnings Growth 155.68%
Reported EPS 12 Trailing Months -0.23
Reported EPS Past Year -0.06
Reported EPS Prior Year 0.05
Net Income Twelve Trailing Months -9,606,000
Net Income Past Year 8,312,000
Net Income Prior Year -14,927,000
Quarterly Revenue Growth YOY -61.60%
5-Year Revenue Growth 13.85%
Operating Margin Twelve Trailing Months -0.18

Balance Sheet
Total Cash Most Recent Quarter 27,409,000
Total Cash Past Year 23,634,000
Total Cash Prior Year 17,111,000
Net Cash Position Most Recent Quarter 6,989,000
Net Cash Position Past Year 3,383,000
Long Term Debt Past Year 20,251,000
Long Term Debt Prior Year 28,187,000
Total Debt Most Recent Quarter 20,420,000
Equity to Debt Ratio Past Year 0.62
Equity to Debt Ratio Most Recent Quarter 0.61
Total Stockholder Equity Past Year 33,569,000
Total Stockholder Equity Prior Year -10,640,000
Total Stockholder Equity Most Recent Quarter 32,437,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 7,171,000
Free Cash Flow Per Share Twelve Trailing Months 0.10
Free Cash Flow Past Year -2,467,000
Free Cash Flow Prior Year -25,628,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.05
MACD Signal 0.04
20-Day Bollinger Lower Band 0.89
20-Day Bollinger Middle Band 1.09
20-Day Bollinger Upper Band 1.29
Beta 0.67
RSI 61.25
50-Day SMA 1.26
150-Day SMA 1.39
200-Day SMA 1.71

System
Modified 11/19/2024 10:21:11 AM EST